ArticleThe Journal of infectious diseases2018
Early Transcriptional Responses After Dengue Vaccination Mirror the Response to Natural Infection and Predict Neutralizing Antibody Titers.
Article in The Journal of infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00831012 (A Phase I Dose Comparison Study of the Safety and Immunogenicity of rDEN3delta30/31-7164, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 3), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I Dose Comparison Study of the Safety and Immunogenicity of rDEN3delta30/31-7164, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 3
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- The disturbance of ABC transporters in patients with dengue fever: integration of metabolomics and transcriptomics.Frontiers in cellular and infection microbiology · 2025Article
- Deciphering Immune Responses to Immunization via Transcriptional Analysis: A Narrative Review of the Current Evidence towards Personalized Vaccination Strategies.International journal of molecular sciences · 2024Review
- Early B cell transcriptomic markers of measles-specific humoral immunity following a 3Frontiers in immunology · 2024Article
- Immunological signatures unveiled by integrative systems vaccinology characterization of dengue vaccination trials and natural infection.Frontiers in immunology · 2024Article
- Phase 1 trial to model primary, secondary, and tertiary dengue using a monovalent vaccine.BMC infectious diseases · 2023Article
- Pathway analysis of host responses to dengue virus serotype 2 infection and inhibition of viral envelope protein by naringenin fromJournal of biosciences · 2023Article
- A robust host-response-based signature distinguishes bacterial and viral infections across diverse global populations.Cell reports. Medicine · 2022Article
- A cytotoxic-skewed immune set point predicts low neutralizing antibody levels after Zika virus infection.Cell reports · 2022Article
- Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study.The Lancet. Microbe · 2022Article
- Immunotranscriptomic profiling the acute and clearance phases of a human challenge dengue virus serotype 2 infection model.Nature communications · 2021Article
- Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk.PLoS pathogens · 2021Article
- Anti-dengue Vaccines: From Development to Clinical Trials.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
Abstract
Background: Several promising live attenuated dengue vaccines are in development, but information about innate immune responses and early correlates of protection is lacking. Methods: We characterized human genome-wide transcripts in whole blood from 10 volunteers at 11 time points after immunization with the dengue virus type 3 (DENV-3) component of the National Institutes of Health dengue vaccine candidate TV003 and from 30 hospitalized children with acute primary DENV-3 infection. We compared day-specific gene expression patterns with subsequent neutralizing antibody (NAb) titers. Results: The transcriptional response to vaccination was largely confined to days 5-20 and was dominated by an interferon-associated signature and a cell cycle signature that peaked on days 8 and 14, respectively. Changes in transcript abundance were much greater in magnitude and scope in symptomatic natural infection than following vaccination (maximum fold-change >200 vs 21 postvaccination; 3210 vs 286 transcripts with significant fold-change), but shared gene modules were induced in the same sequence. The abundances of 131 transcripts on days 8 and 9 postvaccination were strongly correlated with NAb titers measured 6 weeks postvaccination. Conclusions: Live attenuated dengue vaccination elicits early transcriptional responses that mirror those found in symptomatic natural infection and provide candidate early markers of protection against DENV infection. Clinical Trials Registration: NCT00831012.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.